EQUITY - Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY

Equipe constitutive du CERPOP, UMR1295, unité mixte INSERM - Université Toulouse III Paul Sabatier
 

2020
  • Jobert A, Laforgue EJ, Grall-Bronnec M, Rousselet M, Péré M, Jolliet P; FAN-Network (Jouanjus E collaborator), Feuillet F, Victorri-Vigneau C. Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients? Eur J Clin Pharmacol. 2021 Feb;77(2):171-177. doi: 10.1007/s00228-020-03007-7.
     
  • Jouanjus E, Wolff V. Cerebrovascular disease in the context of cannabis. La Presse Médicale. 2020;4:364-372. doi : 10.1016/j.lpmfor.2020.07.013 
     
  • Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, Peyrière H, Micallef J; French Addictovigilance Network. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020 Jul-Aug;75(4):343-354. doi: 10.1016/j.therap.2020.06.006.

  • Lapeyre-Mestre M, Jouanjus E. Cardiovascular disorders attributed to cannabis. La Presse Médicale. 2020;4:355-363. doi: 10.1016/j.lpmfor.2020.08.009.
     
  • Mongiatti M, Bayle P, Lagarrigue A, Fabre D, Telmon N, Lapeyre-Mestre M, Jouanjus E. The cardiovascular health of prisoners who use cannabis: An exploratory study among hospitalised prisoners. Therapie. 2020 Nov-Dec;75(6):579-589. doi: 10.1016/j.therap.2020.06.017.
2019
  • Auffret M, Rolland B, Béhal H, Labreuche J, Jouanjus E, Bordet R, Gautier S. A capture-recapture method for estimating the incidence of off-label prescriptions: the example of baclofen for alcohol use disorder in France. Therapie. 2019 Dec;74(6):645-650. doi: 10.1016/j.therap.2019.06.002.
     
  • Coutens B, Mouledous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin A, Guiard BP, Jouanjus E. Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse. Psychopharmacology (Berl). 2019 Jul;236(7):2069-2082. doi: 10.1007/s00213-019-05198-z.
     
  • Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019 Jun;85(6):1260-1269. doi: 10.1111/bcp.13892.
     
  • Jouanjus E, Lapeyre-Mestre M, Nodot M, Roussin A, Franchitto N, Boyes JP, Nasr N, Oustric S, Dupouy J. Teaching Basic Knowledge on Substance Use Disorders: The Impact of e-Learning on Health Professionals. Clin Ther. 2019 Oct;41(10):2154-2161. doi: 10.1016/j.clinthera.2019.07.012.
     
  • Jouanjus E, Micallef J, Mallaret M, Lapeyre-Mestre M. Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol. 2019 Aug 1;22(8):528-530. doi: 10.1093/ijnp/pyz033.
     
  • Micallef J, Jouanjus E, Mallaret M, Lapeyre Mestre M. Détection des signaux du réseau français d’addictovigilance : méthodes innovantes d’investigation, illustrations et utilité pour la santé publique [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health]. Therapie. 2019 Dec;74(6):579-590. French. doi: 10.1016/j.therap.2019.09.005.
     
Mise à jour Décembre 2020